2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Mary Jo Fidler, MD, associate professor, medical oncology, hematology, internal medicine, Rush University Medical Center, discusses osimertinib (Tagrisso) in patients with EGFR T790M-positive non–small cell lung cancer.
Mary Jo Fidler, MD, associate professor, medical oncology, hematology, internal medicine, Rush University Medical Center, discusses osimertinib (Tagrisso) in patients with EGFR T790M-positive non—small cell lung cancer.
In a phase III trial, there was a clear benefit of osimertinib when compared with standard frontline platinum doublet chemotherapy in patients who progressed on a first-generation TKI.